Xeltis

Xeltis is a clinical-stage medical device company based in Zurich, Switzerland, with a significant research and development center in Eindhoven, Netherlands. Founded in 2006 as a spin-off from the University of Zurich, Xeltis focuses on developing restorative cardiovascular devices, particularly innovative "living" heart valves made from bioabsorbable polymers. These valves utilize the body's natural healing process to regenerate functional tissue, aiming to improve long-term outcomes for patients. The company's core technology, Endogenous Tissue Restoration (ETR), encourages the patient's own tissue to grow around the implant, eventually replacing it with new, living tissue. This approach is particularly beneficial for pediatric patients with congenital heart defects, as it reduces the need for multiple surgeries and the complications associated with traditional biological valves. Xeltis is committed to advancing its clinical programs and bringing its restorative cardiovascular devices to market, supported by a strong emphasis on research and collaboration with academic institutions.

• Employees 60
• Founded 2006
• Annual Revenue $8000000
• Total Funding $181512246